COPD Drugs Market in China 2016-2020

COPD drugs market forecast in China

According to the COPD drugs industry analysis, the chronic obstructive pulmonary disease (COPD) drugs market in China is envisaged to witness impressive growth and will post a CAGR of more than 15% over the forecast period. With the increasing population of smokers in the country, the market for COPD drugs in China will have a positive outlook in the coming years. Smoking leads to the damage of airways, air sacs, and the lining of the lungs, and triggers COPD flare-ups. China is the largest producer of tobacco in the world and accounts for nearly 42% of the world’s cigarette production. Also, the WHO has estimated that almost a third of the world’s smoking population is present in China. Moreover, factors like the improving economic conditions of the country have led individuals to smoke more cigarettes annually, which is anticipated to indirectly drive the COPD drugs market during the predicted period.

One of the emerging COPD drugs industry trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs. Moreover, combination therapies reduce COPD-related hospitalizations and result in better treatment outcomes in patients. Therefore, it can be estimated that the increasing use of combinations therapies will increase the patient compliance toward the use of these respiratory drugs, which will, in turn, fuel this market’s growth prospects over the next four years.

COPD drugs market segmentation by drug class in China

• Bronchodilators
• PDE-4 inhibitors
• Steroids
• Combination therapies